Welcome to our dedicated page for FREQ news (Ticker: FREQ), a resource for investors and traders seeking the latest updates and insights on FREQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FREQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FREQ's position in the market.
Frequency Therapeutics (Nasdaq: FREQ) has announced a strategic update on FX-322, its lead candidate for treating acquired sensorineural hearing loss (SNHL). The company will share analysis of day-90 data from its Phase 2a study in late Q1 2021, following improvements seen in a previous Phase 1/2 study. The Phase 2a study aims to confirm hearing signal and assess multiple doses while expanding the program to include age-related and severe SNHL patients. Key milestones include data readouts for Phase 2a by late Q2 2021 and ongoing Phase 1b studies. Management projects significant clinical insights in early 2021.